Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-06
2007-02-06
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254040, C514S255030, C544S363000, C544S367000, C544S395000
Reexamination Certificate
active
10143335
ABSTRACT:
The present invention relates to substituted bis-arylsulfonamide and arylsulfonamide compounds of the general formula (I) or the formula (II), which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.
REFERENCES:
patent: 3876632 (1975-04-01), Sturm et al.
patent: 6342512 (2002-01-01), Kirsch et al.
patent: 6399617 (2002-06-01), Caldirola et al.
patent: 6632838 (2003-10-01), Kirsch et al.
patent: 2003/0149020 (2003-08-01), Bremberg et al.
patent: 24 59 394 (1976-06-01), None
patent: 0331232 (1989-09-01), None
patent: 0815861 (1998-01-01), None
patent: 2033597 (1970-12-01), None
patent: WO 9715555 (1997-05-01), None
patent: WO 9806697 (1998-02-01), None
patent: WO 9827081 (1998-06-01), None
patent: WO 9902502 (1999-01-01), None
patent: WO 9937623 (1999-07-01), None
patent: WO 9938845 (1999-08-01), None
patent: WO 9942465 (1999-08-01), None
patent: WO 0005225 (2000-02-01), None
patent: WO 0012623 (2000-03-01), None
patent: WO 00122073 (2000-03-01), None
patent: WO 2001/16094 (2001-03-01), None
Baxter et al., Amination of NN′-Dibenzenesulphonyl-1,4-benzoquinone Di-imines: Photochemical Formation of Benzimidazoles, Journal of the Chemical Society, Section C, 1968, vol. 14, pp. 1747-1752.
Jones et al., The Medical Benefit of 5-HT Research, Pharmacology, Biochemistry and Behavior, vol. 71, pp. 555-568, 2002.
Hirst et al., Characterization of [1251]-SB-258585 Binding to Human Recombinant and Native 5-HT6 Receptors in Rat, Pig and Human Brain Tissue, British Journal of Pharmacology, vol. 130, No. 7, pp. 1597-1605, Aug. 2000.
Liao et al., New Selective and Potent 5-HT1B/1D Antagonists: Chemistry and Pharmacological Evaluation of N-Piperazinylphenyl Biphenylcarboxamides and Biphenylsulfonamides, Journal of Medicinal Chemistry, vol. 43, No. 3, pp. 517-525 Feb. 10, 2000.
Bromidge et al., “5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide . . . ”, 1999, J.Med. chem., vol. 42;202-205.
Issac et al., “6-Bicyclopiperazinyl1-1-arylsulfonylindoles . . . ”, 2000, Bioorganic & Medicinal Chemistry Letters, vol. 10; 1719-1721, 2000.
Bentley et al., “Effect of the 5-HT6Antagonist, Ro 04-6790 on Food Consumption in Rats Trained to a Fixed Feeding Regime”,British Journal of Pharmacology, 126 (1999): suppl.
Bourson et al., “Involvement of HT6Receptors in Nigro-Striatal Function in Rodents”,British Journal of Pharmacology, 125:1562-1566 (1998).
Dawson et al., “Selective Enhancement of Glutamatergic Neurotransmission in the Frontal Cortex and Dorsal Hippocampus by antagonism of the 5-HT6Receptor”,Monitoring Molecules in Neuroscience, pp. 318-319, Jun. 16-19, 2001.
Dawson et al., “The 5-HT6Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus”,Neuropsychopharmacology, 25(5)P:662-668 (2001).
Dawson et al., “Potentiation of Amphetamine-Induced Changes in Dopamine and 5-HT by a 5-HT6Receptor Antagonist”,Brain Research Bulletin, 59(6):513-521 (2003).
Foley et al., “The 5-HT6ReceptorAntagonist SB-271045 Reverses Scopolamine-Disrupted Consolidation of a Passive Avoidance Task and Ameliorates Spatial Task Deficits in Aged Rats”,Neuropsychopharmacology, 29:93-100 (2004).
Frantz et al., “5-HT6Receptor Antagonism Potentiates the Behavioral and Neurochemical Effects of Amphetamine but not Cocaine”,Neuropharmacology, 42:170-180 (2002).
Lacroix et al., “5-HT6Receptor Antagonist SB-271046 Enhances Extracellular Levels of Monoamines in the Rat Medial Prefrontal Cortex”,Synapse, 51:158-164 (2004).
Matsumoto et al., “Characterization of Endogenous Serotonin-Mediated Regulation of Dopamine Release in Rat Prefrontal Cortex”,European Journal of Pharmacology, 383:39-48 (1999).
Meneses, Role of 5-HT6Receptors in Memory Formation,Drug News&Perspectives, 14(7):396-400 (2001).
Meneses, “Effects of the 5-HT6Receptor Antagonist Ro 04-6790 on Learning Consolidation”,Behavioural Brain Research, 118:107-110 (2001).
Minabe et al., “Effect of the Acute and Chronic Administration of the Selective 5-HT6Receptor Antagonist SB-271046 on the Activity of Midbrain Dopamine Neurons in Rats: In Vivo Electrophysiological Study”,Synapse, 52:20-28 (2004).
Otano et al., “Anxiogenic-Like Effects and Reduced Stereological Counting of Immunolabelled 5-Hydroxytryptamine6Receptos in Rat Nucleus Accumbens by Antisense Oligonucleotides”,Neuroscience, 92(3):1001-1009 (1999).
Riemer et al., “Influence of the 5-HT6Receptor on Acetylcholine Release in the Cortex: Pharmacological Characterization of 4-(2-Bromo-6-pyrrolidine-1-ylpyridine-4-sulfonyl)phenylamine, a Potent and Selective 5-HT6Receptor Antagonist”,J. Med. Chem., 46:1273-1276 (2003).
Roberts et al., “Distribution of 5-HT6Receptors in Rat Brain: An Autoradiographic Binding Study Using the Radiolabelled 5-HT6Receptor Antagonist [125I]SB-258585”,Brain Research, 934:49-57 (2002).
Rogers et al., “5-HT6Receptor Antagonists Enhance Retention of a Water Maze Task in the Rat”,Psychopharmacology, 158:114-119 (2001).
Shirazi-Southall et al., “Effects of Typical and Atypical Antipsychotics and Receptor Selective Compounds on Acetylcholine Efflux in the Hippocampus of the Rat”,Neuropsychopharmacology, 26(5):583-594 (2002).
Sleight et al.,Brit. J. Pharmacol., (1998) 124, 556-562.
Tsai et al., “Association Analysis of the 5-HT6Receptor Polymorphism C267T in Alzheimer's Disease”,Neuroscience Letters, 276:138-139 (1999).
Woolley et al., “A Role for 5-HT6Receptors in Retention of Spatial Learning in the Morris Water Maze”,Neuropharmacology, 41:210-219 (2001).
Woolley et al., “Reversal of a Cholinergic-Induced Deficit in a Rodent Model of Recognition Memory by the Selective 5-HT6Receptor Antagonist, Ro 04-6790”,Psychopharmacology, 170:358-367 (2003).
Woolley et al., “5-HT6Receptors”,Current Drug Targets—CNS&Neurological Disorders, 3:59-79 (2004).
Bremberg Ulf
Caldirola Patrizia
Jensen Annika J.
Johansson Gary
Mott Andrew
Biovitrum AB
Coleman Brenda
Fish & Richardson P.C.
LandOfFree
Arylsulfonamide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylsulfonamide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylsulfonamide compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3884866